<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3304">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349982</url>
  </required_header>
  <id_info>
    <org_study_id>250320</org_study_id>
    <nct_id>NCT04349982</nct_id>
  </id_info>
  <brief_title>ICU Trial in Critical Ill COVID-19 Patients</brief_title>
  <acronym>POINT-C</acronym>
  <official_title>Prospective Observational ICU Trial in Critical Ill COVID-19 Patients (POINT-C) Cardiovascular Risk and the Effects on Myocardial Events in Critical Ill COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to observe the intensive care course in 30-50 COVID-19 patients with&#xD;
      regard to cardiovascular risk factors and biomarkers.&#xD;
&#xD;
      The primary objective of this study is to investigate the cardiovascular risk and its impact&#xD;
      on cardiovascular complications in COVID-19 patients in intensive care units.&#xD;
&#xD;
      This study is designed to investigate correlations and to investigate factors influencing the&#xD;
      course of the new viral disease COVID-19 in intensive care. Previous scientific findings are&#xD;
      still rare due to the relevance of the disease, therefore this study is also explorative and&#xD;
      not exclusively based on a hypothesis.&#xD;
&#xD;
      The cardiovascular risk will be assessed upon admission to the intensive care unit and&#xD;
      subsequently the course of biomarkers (see below) will be analysed in a cohort study (no, low&#xD;
      and high cardiovascular risk).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective observational study the course of 30-50 intensive care patients of the&#xD;
      University Hospital of Graz is analysed.&#xD;
&#xD;
      It is not possible to give an exact number of cases, because it is not possible to estimate&#xD;
      exactly how many COVID-19 patients will be admitted to the listed intensive care units in&#xD;
      Graz. Recruitment will start when approved from the ethical board and end in June, 2020.&#xD;
&#xD;
      Inclusion criteria&#xD;
&#xD;
        -  Admission on an isolation unit - intensive care unit of the University Clinic of Graz&#xD;
&#xD;
        -  Detection of a SARS - CoV-2 infection by PCR (tracheal or pharyngeal secretion) or CT&#xD;
           examination (with consecutive PCR confirmation)&#xD;
&#xD;
        -  male and female sex&#xD;
&#xD;
        -  subordinated declaration of consent if possible*&#xD;
&#xD;
        -  respiratory insufficiency with indication for non-invasive or invasive ventilation&#xD;
           during admission to an intensive care unit&#xD;
&#xD;
      Informed consent&#xD;
&#xD;
      Since the study patients are intensive care patients, it may happen that the informed consent&#xD;
      cannot be obtained at the time of admission to the intensive care unit (e.g.: patient is not&#xD;
      able to give consent due to mechanical ventilation), in this case the informed consent will&#xD;
      be obtained at a later time (e.g.: at the latest upon discharge from the intensive care&#xD;
      unit/hospital.&#xD;
&#xD;
      (* In exceptional cases it may happen that patients cannot sign a declaration of consent at&#xD;
      admission as well as at discharge from the intensive care unit (e.g.: during the stay&#xD;
      continuous mechanical ventilation and death at the intensive care unit).&#xD;
&#xD;
      Study related measures&#xD;
&#xD;
      In addition to the standardized routine laboratory (daily, in the morning approx. 05.00&#xD;
      o'clock), a lipid profile (LDL cholesterol, triglycerides, Lpa, HDL cholesterol, total&#xD;
      cholesterol) is taken once upon admission to the intensive care unit in order to determine&#xD;
      the cardiovascular risk upon admission to the intensive care unit. This lipid profile is&#xD;
      taken with the aid of a vacuette (9 ml corresponds to approx. 2 teaspoons of whole blood).&#xD;
&#xD;
      Study related patient questionnaire for the determination of cardiovascular risk&#xD;
&#xD;
      The patient questionnaire should be filled out by interviewing the patients at the time of&#xD;
      admission to the intensive care unit. If the condition of the patients does not allow this,&#xD;
      the information in the questionnaire should be carried out by a member of the study staff by&#xD;
      researching the patient's medical history (e.g. doctor's letters, electronic data&#xD;
      acquisition, etc.). The questionnaire is used to assess the cardiovascular risk (contains&#xD;
      medication, past medical history).&#xD;
&#xD;
      Non-study-related measures (standardised routine analyses in an intensive care unit)&#xD;
&#xD;
      To determine the cardiovascular risk:&#xD;
&#xD;
      See Patient Questionnaire, Lipid Status, HbA1c&#xD;
&#xD;
      For follow-up (daily routine laboratory checks):&#xD;
&#xD;
      Blood count, coagulation, liver and kidney counts, triglycerides, biomarkers (CK, CK-MB,&#xD;
      TropT, NTproBNP, CRP, PCT, IL-6, D-dimer, LDH, myoglobin).&#xD;
&#xD;
      Other parameters and therapies that are considered in the evaluation or that are used to&#xD;
      create the data set:&#xD;
&#xD;
      Fluid introduction, fluid discharge, balance, prone positioning, non-invasive ventilation&#xD;
      (PEEP, fiO2), invasive ventilation (ventilation mode, PEEP, Pinsp, fiO2, AF), respiration&#xD;
      (respiratory rate, fiO2, SpO2, paO2, pCO2, etCO2), circulation parameters (RR syst, RR dia,&#xD;
      MAP, HF, ECG (rhythm, Qtc)), extracorporeal organ support procedures, mortality, med.&#xD;
      complications, entire drug therapy (e.g: norepinephrine (incl. dose), levosimendan (incl.&#xD;
      dose), vasopressin (incl. dose), cortisone (incl. dose), dobutamine (incl. dose), supportive&#xD;
      therapy (zinc, vitamin C, selenium), antifungal and antibiotic therapy, hydroxychloroquine,&#xD;
      lopinavir, remdesivir, favipiravir, tocilizumab.&#xD;
&#xD;
      Anonymisation of patients&#xD;
&#xD;
      After enrolment in the study, the patient data is encoded/pseudo-anonymised, i.e. patients&#xD;
      are identified with a consecutive ID number (neither name, initials nor laboratory&#xD;
      requirement number are recorded). To find out the previous illnesses of intensive care&#xD;
      patients it is necessary to create a list of patient names and the corresponding ID numbers&#xD;
      for pseudonymisation. This list remains with the investigator.&#xD;
&#xD;
      Use of clinical data For the statistical analysis, clinical data in pseudo-anonymised/encoded&#xD;
      form are used, e.g. diagnosis, concomitant diseases, long-term medication, intensive care&#xD;
      therapy, medication, smoking, age, sex.&#xD;
&#xD;
      Should further questions arise during the study regarding this patient collective, the&#xD;
      collected data would be used for further evaluations.&#xD;
&#xD;
      Centre/intensive care units The test centre is the LKH Univ.Klinikum Graz, Auenbruggerplatz&#xD;
      5, A-8036 Graz. Patients are admitted to the SARS - CoV-2 (COVID-19) isolation unit intensive&#xD;
      care units of the LKH University Hospital Graz.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>ICU CV risk and Biomarker (e.g. Troponin)</measure>
    <time_frame>through study completion, up to 4 weeks</time_frame>
    <description>Troponin courses in the intensive care unit are analyzed in consideration of the respective cardiovascular risk.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CV risk and Outcome during ICU stay</measure>
    <time_frame>through study completion, up to 4 weeks</time_frame>
    <description>The 30-day mortality during the ICU stay is determined and divided into appropriate cardiovascular risk groups.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Risk Factor, Cardiovascular</condition>
  <condition>Covid19</condition>
  <condition>Critical Illness</condition>
  <condition>Course Illness</condition>
  <arm_group>
    <arm_group_label>No cardiovascular risk</arm_group_label>
    <description>If no patients with no cardiovascular risk can be included in the study, we will divide the cohorts into different categories (e.g. low, medium and high cardiovascular risk).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low cardiovascular risk</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>high cardiovascular risk</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biomarker (TropT, Myoglobin, CK, CK-MB, LDH, D-dimer, CRP, PCT)</intervention_name>
    <description>Factorial</description>
    <arm_group_label>No cardiovascular risk</arm_group_label>
    <arm_group_label>high cardiovascular risk</arm_group_label>
    <arm_group_label>low cardiovascular risk</arm_group_label>
    <other_name>Fluid management (fluid input, fluid output), prone positioning, ventilation, respiration, circulation parameters, extracorporeal organ support procedures, mortality, MACE, entire drug therapy</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Lipid profile once at intensive care unit admission (9 ml whole blood).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with respiratory insufficiency and current COVID-19 infection with different&#xD;
        gender, age and previous diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Admission on an isolation unit - intensive care unit of the LKH Univ. Klinikum Graz&#xD;
&#xD;
          -  Detection of a SARS - CoV-2 infection by PCR (tracheal or pharyngeal secretion) or CT&#xD;
             examination (with subsequent PCR detection)&#xD;
&#xD;
          -  male and female sex&#xD;
&#xD;
          -  subordinated declaration of consent if possible if applicable&#xD;
&#xD;
          -  respiratory insufficiency with indication for non-invasive or invasive ventilation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  if the inclusion criteria are not met&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Rief, Dr.</last_name>
    <phone>(+43)0316-385</phone>
    <phone_ext>84661</phone_ext>
    <email>martin.rief@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Klivinyi, Dr.</last_name>
    <phone>(+43)0316-385</phone>
    <phone_ext>13027</phone_ext>
    <email>christoph.klivinyi@medunigraz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Rief, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5.</citation>
    <PMID>32139904</PMID>
  </reference>
  <reference>
    <citation>Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, Bi Z, Zhao Y. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020 May;109(5):531-538. doi: 10.1007/s00392-020-01626-9. Epub 2020 Mar 11. Review.</citation>
    <PMID>32161990</PMID>
  </reference>
  <reference>
    <citation>Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391. doi: 10.1016/j.pcad.2020.03.001. Epub 2020 Mar 10. Review.</citation>
    <PMID>32169400</PMID>
  </reference>
  <reference>
    <citation>Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020 May;94:91-95. doi: 10.1016/j.ijid.2020.03.017. Epub 2020 Mar 12.</citation>
    <PMID>32173574</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 10, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Martin Rief</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Critical Illness</keyword>
  <keyword>Covid19</keyword>
  <keyword>Risk Factor, Cardiovascular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin fragment D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>If other researchers need the medical data of this study for their research projects, the data will be made available after consideration.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

